Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gossamer Bio, Inc. - Common Stock (NQ:GOSS)

2.940 +0.430 (+17.13%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gossamer Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Why Kaival Brands Innovations Shares Are Trading Lower By 47%? Here Are Other Stocks Moving In Friday's Mid-Day Session
 
Via Benzinga
The Penny Stock Pundits: 3 Companies Poised to Become the Talk of Wall Street
Taking a small position in these penny stocks today could have you sitting on a sizable gain by the time Wall Street starts to pile in. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for Gossamer Bio: Here's What You Need To Know
 
Via Benzinga
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference
From Gossamer Bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Gossamer Bio, Inc.
Via Business Wire
GOSS Stock Earnings: Gossamer Bio Misses EPS for Q1 2024
GOSS stock results show that Gossamer Bio missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Collaborates With Italian Drugmaker Chiesi To Advance Lung Health Solutions Worldwide
Gossamer Bio partners with Chiesi Farmaceutici to develop and market seralutinib globally, targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung... 
Via Benzinga
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine
From Gossamer Bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors
From Gossamer Bio, Inc.
Via Business Wire
Goldman Sachs Maintains Buy Rating for Gossamer Bio: Here's What You Need To Know
 
Via Benzinga
GOSS Stock Earnings: Gossamer Bio Meets EPS for Q4 2023
GOSS stock results show that Gossamer Bio met analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
7 Micro-Cap Stocks That Could Majorly Surprise Investors
Although extremely small enterprises can be terrifyingly risky, these micro-cap stock surprises deserve a closer look. 
Via InvestorPlace
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Gossamer Bio, Inc.
Via Business Wire
Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Appoints Bob Smith as Chief Commercial Officer
From Gossamer Bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors
From Gossamer Bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.